Carboplatin (AUC 5) with oral vinorelbine (VNR) d 1,8 at 50 mg/m2 (level 1, L1) or 60 mg/m2 (level 2, L2) every 3 weeks: A phase I study
Nikunj Patel(Nirma University), Franco M. Muggia(NYU Langone Health), Samantha Moore, B. Norwood, M. Wendell, M. Fink, Richard L. Chang, Minerva Utate(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Andrea Downey(University of New Mexico), Jason Gatewood(University of Kansas Medical Center)
Cited by 1
Related Papers
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
|Journal of Clinical Oncology|2005|100
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
|Journal of Clinical Oncology|1996|87
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
|Annals of Oncology|2007|83